Table 2.
rwPFS With I-O Monotherapy Stratified by Subgroup.
| Squamous NSCLC |
Non-squamous NSCLC |
|||||||
|---|---|---|---|---|---|---|---|---|
| n | Median rwPFS (95% CI), Months | 12-Month rwPFS Rate, % | 24-Month rwPFS Rate, % | n | Median rwPFS (95% CI), Months | 12-Month rwPFS Rate, % | 24-month rwPFS Rate, % | |
| All patients | 875 | 4.2 (3.6–5.2) | 25.4 | 11.2 | 2166 | 4.6 (4.1–5.2) | 30.3 | 18.2 |
| Age, years | ||||||||
| <65 | 167 | 2.9 (2.3–4.9) | 19.5 | 8.4 | 534 | 4.3 (3.5–5.9) | 33.1 | 22 |
| ≥65 to <75 | 302 | 5.1 (3.5–6.2) | 27.9 | 13.4 | 673 | 4.1 (3.6–5.0) | 27.8 | 19.6 |
| ≥75 | 406 | 4.3 (3.4–5.4) | 26 | 10.6 | 959 | 5.1 (4.2–5.7) | 30.6 | 15.1 |
| Tumor PD-L1 expression | ||||||||
| <1% | 52 | 4.2 (2.8–10.0) | 27.5 | 16.8 | 102 | 4.2 (3.4–6.1) | 24.5 | 14.3 |
| 1%–49% | 157 | 3.1 (2.7–4.4) | 23.2 | 8.2 | 239 | 2.8 (2.3–3.4) | 20.5 | 10.9 |
| ≥50% | 536 | 5.2 (3.9–5.9) | 27.6 | 12.3 | 1582 | 5.1 (4.2–5.7) | 31.9 | 19.5 |
| Unknown | 130 | 3.3 (2.6–4.9) | 17.5 | 7 | 243 | 4.9 (3.4–6.1) | 31.2 | 17.9 |
| Brain metastases | ||||||||
| With | 42 | 2.5 (1.3–3.4) | 13.4 | 8.9 | 317 | 3.5 (2.7–4.6) | 27.8 | 15.8 |
| Without | 833 | 4.5 (3.8–5.4) | 26 | 11.4 | 1849 | 4.8 (4.2–5.4) | 30.8 | 18.6 |
CI, confidence interval; I-O, immuno-oncology; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; rwPFS, real-world progression-free survival.